Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation and participation in… read more.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association… read more.
Pfizer Inc will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30… read more.
Incyte announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago…. read more.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, announced that the full results from the… read more.
Bayer and Vividion Therapeutics, Inc. will present the latest research on their advancing oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place… read more.
Johnson & Johnson MedTech announced 12-month results from the SmartfIRE study, presented as a late-breaking presentation at the annual meeting of the European Heart Rhythm Association (EHRA) in… read more.
United Therapeutics Corporation announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on… read more.
PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel… read more.
Novo Nordisk presented the full results from STRIDE, a phase III peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic (semaglutide 1.0 mg) in… read more.
Results from a Phase 3 study of treatment with investigational tolebrutinib show a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing… read more.
AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
